ATAI Life Sciences NV Cash Flow Conversion Efficiency
ATAI Life Sciences NV cash flow conversion efficiency. Based on the latest financial reports, ATAI Life Sciences NV (9VC) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-23.26 Million ≈ $-27.19 Million USD) by net assets (€159.91 Million ≈ $186.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ATAI Life Sciences NV (2019–2024)
Cash flow conversion efficiency of ATAI Life Sciences NV from 2019 to 2024. This chart illustrates how ATAI Life Sciences NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for ATAI Life Sciences NV for real-time trading data and today's change.
ATAI Life Sciences NV Cash Flow Conversion Ratio Explained
ATAI Life Sciences NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ATAI Life Sciences NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences NV ranked by their cash flow conversion efficiency. Also see ATAI Life Sciences NV market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Del Monte Corporation
NYSE:DMC
|
0.027x |
|
Aygaz AS
IS:AYGAZ
|
0.003x |
|
MilDef Group AB
ST:MILDEF
|
0.012x |
|
REX American Resources Corporation
NYSE:REX
|
-0.003x |
|
Edelweiss Financial Services Limited
NSE:EDELWEISS
|
-0.118x |
|
Hefei Jianghang Aircraft Equipment Corporation Ltd
SHG:688586
|
-0.030x |
|
Orezone Gold Corp
TO:ORE
|
0.301x |
|
Shanghai Luxin Packing Materials Science&Technology Co Ltd
SHE:002565
|
0.007x |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences NV (2019–2024)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences NV from 2019 to 2024. Review 9VC FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €116.55 Million ≈ $136.26 Million |
€-82.44 Million ≈ $-96.38 Million |
-0.707x | -105.43% |
| 2023-12-31 | €244.32 Million ≈ $285.63 Million |
€-84.12 Million ≈ $-98.34 Million |
-0.344x | +12.41% |
| 2022-12-31 | €265.77 Million ≈ $310.71 Million |
€-104.47 Million ≈ $-122.13 Million |
-0.393x | -139.88% |
| 2021-12-31 | €385.96 Million ≈ $451.23 Million |
€-63.25 Million ≈ $-73.94 Million |
-0.164x | +24.74% |
| 2020-12-31 | €95.37 Million ≈ $111.50 Million |
€-20.77 Million ≈ $-24.28 Million |
-0.218x | -65.51% |
| 2019-12-31 | €59.64 Million ≈ $69.72 Million |
€-7.85 Million ≈ $-9.17 Million |
-0.132x | -- |
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more